MX2018010971A - Compuestos y métodos para modular la tirosina cinasa de bruton. - Google Patents

Compuestos y métodos para modular la tirosina cinasa de bruton.

Info

Publication number
MX2018010971A
MX2018010971A MX2018010971A MX2018010971A MX2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A MX 2018010971 A MX2018010971 A MX 2018010971A
Authority
MX
Mexico
Prior art keywords
bruton
modulating
compounds
methods
tyrosine kinase
Prior art date
Application number
MX2018010971A
Other languages
English (en)
Inventor
A Miller Richard
Verner Erik
Hudson Ryan
- Marie Beausoleil Anne
Original Assignee
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvus Pharmaceuticals Inc filed Critical Corvus Pharmaceuticals Inc
Publication of MX2018010971A publication Critical patent/MX2018010971A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

En la presente se proporcionan, entre otros, compuestos y métodos para modular la tirosina cinasa de Bruton.
MX2018010971A 2016-03-11 2017-03-10 Compuestos y métodos para modular la tirosina cinasa de bruton. MX2018010971A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662307399P 2016-03-11 2016-03-11
US201662342004P 2016-05-26 2016-05-26
PCT/US2017/021966 WO2017156495A1 (en) 2016-03-11 2017-03-10 Compounds and methods for modulating bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
MX2018010971A true MX2018010971A (es) 2019-03-28

Family

ID=59789888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010971A MX2018010971A (es) 2016-03-11 2017-03-10 Compuestos y métodos para modular la tirosina cinasa de bruton.

Country Status (13)

Country Link
US (2) US10870652B2 (es)
EP (1) EP3426637B1 (es)
JP (1) JP6972002B2 (es)
KR (1) KR102416971B1 (es)
CN (2) CN115746000A (es)
AU (1) AU2017230098B2 (es)
CA (1) CA3017567A1 (es)
ES (1) ES2912465T3 (es)
IL (1) IL261583A (es)
MX (1) MX2018010971A (es)
PL (1) PL3426637T3 (es)
WO (1) WO2017156495A1 (es)
ZA (1) ZA201805951B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554118B2 (en) 2017-03-22 2023-01-17 Xibin Liao Bruton's tyrosine kinase inhibitors

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6972002B2 (ja) * 2016-03-11 2021-11-24 エンジェル・ファーマシューティカル・カンパニー・リミテッド ブルトン型チロシンキナーゼを調節する化合物及び方法
JOP20190113A1 (ar) * 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
KR102384924B1 (ko) * 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN108191871B (zh) * 2018-01-02 2020-02-18 成都倍特药业有限公司 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN111662232B (zh) * 2019-03-06 2022-08-02 中国科学院上海药物研究所 具有2h-吲唑结构的小分子化合物及其合成和应用
CA3133004A1 (en) 2019-05-31 2020-12-03 Sichuan Haisco Pharmaceutical Co., Ltd. Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof
WO2020252397A1 (en) * 2019-06-12 2020-12-17 Baylor College Of Medicine Small molecule proteolysis-targeting chimeras and methods of use thereof
LT4036095T (lt) * 2019-09-26 2024-03-25 Jumbo Drug Bank Co., Ltd. 4-fluor-1h-pirazolo[3,4-c]piridino dariniai kaip selektyvūs brutono tirozino kinazės (btk) inhibitoriai, skirti gydyti b ląstelių limfomą ir autoimunines ligas
WO2022253250A1 (zh) * 2021-06-01 2022-12-08 正大天晴药业集团股份有限公司 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
US20230115350A1 (en) * 2021-07-29 2023-04-13 Cedilla Therapeutics, Inc. Tead inhibitors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1353605A (zh) * 1999-03-26 2002-06-12 欧洲凯尔特股份有限公司 芳基取代的吡唑、咪唑、噁唑、噻唑和吡咯及其应用
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
RS51981B (en) 2005-12-13 2012-02-29 Schering Corporation POLYCYCLIC INDASOL DERIVATIVES WHICH ARE ERK INHIBITORS
CA2641254A1 (en) * 2006-02-14 2007-08-23 Vertex Pharmaceuticals Incorporated Pyrrolo(3,2-c) pyridines useful as inhibitors of protein kinases
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
US20120101113A1 (en) * 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
ES2396613T3 (es) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
ES2660418T3 (es) * 2008-07-16 2018-03-22 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos
EP2328895B1 (en) 2008-09-16 2013-03-27 Proximagen Limited Pyrazolo[4,3-c]pyridine compounds and their use as inhibitors of SSAO
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
KR101301533B1 (ko) * 2010-02-09 2013-09-04 한미사이언스 주식회사 암세포 성장 억제 효과를 갖는 신규 피리미딘 유도체
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2809673B1 (en) 2012-01-31 2016-11-02 Nanjing Allgen Pharma Co. Ltd. Spirocyclic molecules as bruton's tyrosine kinase inhibitors
WO2014022569A1 (en) 2012-08-03 2014-02-06 Principia Biopharma Inc. Treatment of dry eye
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
KR20230170797A (ko) 2013-10-25 2023-12-19 파마싸이클릭스 엘엘씨 이식편 대 숙주 질환의 치료 및 예방 방법
WO2015124570A1 (en) 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
WO2017066014A1 (en) 2015-10-14 2017-04-20 Sunnylife Pharma Inc. Bruton's tyrosine kinase inhibitors
WO2017127371A1 (en) * 2016-01-21 2017-07-27 Sunnylife Pharma Inc. Bruton's tyrosine kinase inhibitors
JP6972002B2 (ja) * 2016-03-11 2021-11-24 エンジェル・ファーマシューティカル・カンパニー・リミテッド ブルトン型チロシンキナーゼを調節する化合物及び方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11554118B2 (en) 2017-03-22 2023-01-17 Xibin Liao Bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO2017156495A1 (en) 2017-09-14
AU2017230098A1 (en) 2018-09-20
CN115746000A (zh) 2023-03-07
AU2017230098B2 (en) 2021-03-25
KR102416971B1 (ko) 2022-07-04
CN109071455B (zh) 2022-08-02
US11306099B1 (en) 2022-04-19
IL261583A (en) 2018-10-31
CA3017567A1 (en) 2017-09-14
JP2019507793A (ja) 2019-03-22
ES2912465T3 (es) 2022-05-26
EP3426637A4 (en) 2019-09-18
US10870652B2 (en) 2020-12-22
KR20180133415A (ko) 2018-12-14
JP6972002B2 (ja) 2021-11-24
EP3426637B1 (en) 2022-02-09
WO2017156495A8 (en) 2018-09-27
ZA201805951B (en) 2020-12-23
PL3426637T3 (pl) 2022-05-30
US20190106423A1 (en) 2019-04-11
CN109071455A (zh) 2018-12-21
EP3426637A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
MX2019005076A (es) Compuestos y métodos para modular la cinasa de linfocitos t inducible por interleucina 2.
EA201992497A1 (ru) МОДУЛЯТОРЫ K-Ras
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2019007021A (es) Anticuerpos il-11ra.
MX2019007020A (es) Anticuerpos il-11.
MX2018008815A (es) Inhibidores de tirosina quinasa de bruton.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
AU2018258581A8 (en) RAF-degrading conjugate compounds
MY191581A (en) Anti-pd-1 antibodies
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2019011116A (es) Inhibidores de la tirosina quinasa de bruton.
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
MX2018012176A (es) Anticuerpos anti-factor bb del complemento y usos de estos.
PH12018502233A1 (en) ErbB INHIBITORS AND USES THEREOF
SG11201811429XA (en) Flow reactor
PH12021550413A1 (en) Vitamin d pediatric dosage forms, methods of making and using
MX2021003159A (es) Microemulsiones que contienen antioxidantes.
MX2020006398A (es) Compuestos y composiciones para tratar la fibrosis.
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.